Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 17, 2019
First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation
NANTES, France, July 17, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announces a scientific publication in the American Journal of Transplantation(1). This ...
July 17, 2019
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF
ARCHAMPS, France, July 17, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) a biopharmaceutical company and the leader in NOX therapies, announced today that ...
July 17, 2019
Nicox: Second Quarter 2019 Business Update and Financial Highlights
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Q2 2019 operational highlights, revenue and cash position for Nicox and its subsidiaries ...
July 17, 2019
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced that ...
July 17, 2019
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in ...
July 17, 2019
DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission
CUPERTINO, Calif., July 17, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged that the submission of ...
July 17, 2019
CorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs
BERKELEY HEIGHTS, N.J., July 17, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
July 17, 2019
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency
VANCOUVER, July 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve ...
July 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
HOLON, Israel, July 16, 2019 /PRNewswire/ -- Compugen Ltd.(CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United ...
July 16, 2019
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
SAN DIEGO and TORONTO, July 16, 2019 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting ...
July 16, 2019
Vermillion Announces Publication of New Study Demonstrating Overa’s Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone
Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced publication of a paper entitled: “Clinical Performance Comparison of Two In-Vitro ...
July 16, 2019
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
CRANBURY, N.J., July 16, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ...
July 16, 2019
MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds
YAVNE, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
July 16, 2019
Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina
VANCOUVER, July 16, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve ...
July 16, 2019
Valneva Announces Drawdown of Further €10 million from its Existing European Investment Bank Loan
Saint Herblain (France), July 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major ...
July 16, 2019
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-ANG3 for ...
July 15, 2019
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for Arfolitixorin
GOTHENBURG, Sweden, July 15, 2019 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the outcome of an advisory board meeting ...
July 15, 2019
Orphazyme appoints Kim Stratton as Chief Executive Officer
Copenhagen, July 15, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company’s ...
July 15, 2019
RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019
TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a ...
July 15, 2019
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
GAITHERSBURG, Md., July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of ...
Page 1 of 153